Related Experiment Video

Updated: May 25, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Molecular basis of triple negative breast cancer and implications for therapy

Parvin F Peddi1, Matthew J Ellis, Cynthia Ma

  • 1Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.

International Journal of Breast Cancer
|February 2, 2012
PubMed

Insights

Triple negative breast cancer (TNBC) is aggressive with few treatments. Genomic studies reveal TNBC is molecularly diverse, highlighting needs for targeted therapies and new clinical trial designs.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Triple negative breast cancer (TNBC) represents an aggressive subtype of breast cancer.
  • Current treatment options for TNBC are limited, lacking proven targeted therapies.
  • Understanding the underlying molecular mechanisms of TNBC is essential for advancing treatment strategies.

Purpose of the Study:

  • To investigate the molecular heterogeneity of triple negative breast cancer.
  • To identify potential therapeutic targets for TNBC based on its genomic profile.
  • To inform the design of future clinical trials for TNBC.

Main Methods:

  • Genome-wide gene expression profiling.
  • DNA sequencing studies to identify somatic mutations.
  • Analysis of genomic structural changes.

Main Results:

  • Triple negative breast cancer is characterized by significant molecular heterogeneity.
  • Multiple somatic mutations and genomic structural alterations are prevalent in TNBC.
  • These molecular findings provide a basis for targeted therapeutic approaches.

Conclusions:

  • TNBC is not a single disease but a collection of molecularly distinct subtypes.
  • Targeted drug development requires addressing this heterogeneity.
  • Future clinical trials should be designed to accommodate the diverse molecular landscape of TNBC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...